AUA2019 076IC - Advanced OAB Therapies - What To Do When 1st And 2nd Line Therapies Do Not Work
AUAUniversity30 Touko 2019

AUA2019 076IC - Advanced OAB Therapies - What To Do When 1st And 2nd Line Therapies Do Not Work

Support provided by an independent educational grant from Allergan, Astellas and Medtronic CME Available: https://auau.auanet.org/node/24581 Instructional Course Director(s) Kathleen Kobashi, MD, FACS, FPMRS Virginia Mason Medical Center Instructional Course Faculty(s) Sandip Vasavada, MD Professor of Surgery/Urology Cleveland Clinic Glickman Urological Institute and Lerner College of Medicine David Ginsberg, MD USC Institute of Urology This course would aim to discuss all guidelines-approved 3rd line therapies for the treatment of overactive bladder (OAB). Case–based discussion will be used adjunctively to illustrate how best to select patients in varying clinical scenarios and how to optimally counsel a patient on each of the available modalities, including onabotulinumtoxinA injection of the bladder, tibial nerve stimulation, and sacral nerve stimulation (SNS). Emerging therapies in neuromodulation will also be introduced. Optimal patient selection and integration of these therapies into the urology practice will be discussed in detail. Importantly, the technique of onabotulinumtoxinA injection, ideal tibial nerve stimulation, optimal SNS lead placement, and troubleshooting of the failed implant will be highlighted. Learning Objectives: Name the available 3rd line therapies for treatment of refractory OAB Practice the the injection technique for onabotulinumtoxinA for OAB Employ the technique of tibial nerve stimulation for OAB Indicate the optimal lead placement for sacroneuromodulation and troubleshooting the failed implant Identify the upcoming 3rd line therapies for OAB

Jaksot(422)

Incorporating New IO Therapies - How to Properly Administer IO Therapies in an Infusion Suite

Incorporating New IO Therapies - How to Properly Administer IO Therapies in an Infusion Suite

To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of ...

29 Loka 201837min

Immuno-Oncology: A Focus on Bladder Cancer

Immuno-Oncology: A Focus on Bladder Cancer

Immuno-Oncology: A Focus on Bladder Cancer is the second in the 4-part series. Topics will include "non muscle invasive disease" and "muscle invasive disease" as well as "clinical trial evidence" and ...

24 Loka 201854min

AUA2018 Residents Forum: Public Policy and Advocacy in Urology: A Primer for Residents

AUA2018 Residents Forum: Public Policy and Advocacy in Urology: A Primer for Residents

Speakers: Christopher M. Gonzalez, MD, MBA James M. Dupree, MD, MPH

22 Loka 201817min

Incorporating New IO Therapies - Managing Patient Side Effects

Incorporating New IO Therapies - Managing Patient Side Effects

To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of ...

19 Loka 201830min

Immuno - Oncoloy: A New Class Of Drugs

Immuno - Oncoloy: A New Class Of Drugs

Immuno-Oncology: A New Class of Drugs is the first in the 4-part series. Topics will include "Tumor Immunotherapy", "Immunotherapy Drug Availability and Mechanisms of Action", "Vaccines", "Monoclonal ...

10 Loka 201842min

Androgen Axis Agents and Bone Target Therapies in Advanced Prostate Cancer

Androgen Axis Agents and Bone Target Therapies in Advanced Prostate Cancer

Androgen Axis Agents and Bone Target Therapies in Advanced Prostate Cancer: What's New is the third podcast in a 4-part series. Topics will include "Manipulating the Androgen Axis: Androgen Biosynthe...

8 Loka 201856min

Incorporating New IO Therapies - Biomarkers

Incorporating New IO Therapies - Biomarkers

To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of ...

4 Loka 201829min

Castration-Resistant Prostate Cancer (CRPC) Guideline Amendment

Castration-Resistant Prostate Cancer (CRPC) Guideline Amendment

To encourage consistent, high quality, evidence-based treatment of patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC), the AUA and Urology Care Foundation are producing a serie...

28 Syys 201851min

Suosittua kategoriassa Koulutus

rss-murhan-anatomia
psykopodiaa-podcast
rss-narsisti
voi-hyvin-meditaatiot-2
aamukahvilla
rss-niinku-asia-on
rss-liian-kuuma-peruna
adhd-podi
psykologia
kesken
rss-vapaudu-voimaasi
rss-valo-minussa-2
dear-ladies
rss-koira-haudattuna
jari-sarasvuo-podcast
esa-saarinen-filosofia-ja-systeemiajattelu
leveli
rss-duodecim-lehti
rss-luonnollinen-synnytys-podcast
rss-ihana-elamani